More News

Mironid raises $46m to advance clinical development of rare kidney disease treatment

Jim Cornall -
Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a...

Foundation for Angelman Syndrome Therapeutics announces agreement with Apertura Gene Therapy for access to blood-brain barrier-crossing capsid

Jim Cornall -
The Foundation for Angelman Syndrome Therapeutics (FAST), a patient advocacy organisation working to support the development of transformative treatment...

3D genome mapping in rare immune cells reveals new Crohn’s genes

Jim Cornall -
A new study co-led by Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published...

Cancer cells hijack a fatty acid to escape immune attack in liver metastases

Jim Cornall -
Liver metastases are among the most common and deadly forms of cancer spread. Now, researchers at VIB and KU...

Collaboration aims to develop new class of medicines for in vivo CAR-T

Jim Cornall -
Sail Biomedicines has announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor...

Data validates new method for single-cell transcriptomic tumour profiling from clinical pathology samples

Jim Cornall -
One Biosciences has announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded...

White paper looks at early clinical development of B-cell depletion therapies in autoimmune disease

Jim Cornall -
Novotech, a clinical research organisation (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in...

3D genome mapping in rare immune cells reveals new Crohn’s disease genes

Jim Cornall -
A new study co-led by Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published...

Elix and University of Vienna agree to use AI to advance drug discovery

Jim Cornall -
Elix, Inc. and the University of Vienna, Austria, have signed a joint research agreement aimed at advancing drug discovery...

KAIST develops way to combat cancer cachexia

Jim Cornall -
A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away. A KAIST...

A better way to deliver mitochondria into living cells

Jim Cornall -
Inside almost every cell in our body are tiny structures called organelles that keep us alive and functioning. Among...

Thyora Therapeutics launches to build platform for covalent drug discovery

Jim Cornall -
Thyora Therapeutics has emerged from stealth to leverage next-generation covalent chemistry, with a mission to accelerate clinical translation and...

Base to Base biotech podcast 70: Taking the lead on GI motility disorders

Jim Cornall -
This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders. Base...

Cancer immunotherapy and gene therapy in a single nanoparticle

Jim Cornall -
Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer...

New data from DM1 study

Jim Cornall -
Arthex Biotech has published new preclinical data demonstrating central nervous system (CNS) activity of its investigational antimiR-23b therapy, ATX-01,...

Synaptiq Therapeutics launches with acquisition of SYN-001 programme

Jim Cornall -
A consortium of European and US-based investors and Nobias Therapeutics has launched Synaptiq Therapeutics, a privately held, clinical-stage biotechnology...

Collaboration to develop first medicine for newly identified ReNU syndrome

Jim Cornall -
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit, have announced a strategic collaboration and global exclusive license...

Body’s natural recycling system could help reduce inflammation

Jim Cornall -
Researchers at VIB and KU Leuven in Belgium, together with international collaborators, have discovered that blocking autophagy – the...

Crystalys Therapeutics raises $130m for gout treatment

Jim Cornall -
Crystalys Therapeutics Inc. has closed an oversubscribed $130m Series B financing to support the late-stage global clinical development and...

Boost to biotech in Virginia with lab capacity increase

Jim Cornall -
Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, has expanded its Bio+Tech Center to support...

AI and sleep analysis help early diagnosis of Alzheimer’s

Jim Cornall -
Researchers from Universidad Carlos III de Madrid (UC3M) and Hospital Universitario Severo Ochoa in Leganés, part of the public...